Orchid Pharma Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Orchid Pharma Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 24% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 94% of Healthcare companies in India.
- Growth Efficiency Ratio: Sales grew 83% in 3 years, but profit fell: ₹7 less profit per ₹100 of extra sales. Lower than 90% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹128Over the last 3 years, every ₹100 of reported profit came with ₹128 of operating cash.
Higher than 58% of Healthcare companies in India.
Self-Funding Ratio
0.5×Over the last 3 years its own operating cash paid for 50% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Lower than 81% of Healthcare companies in India.
Cash Locked Ratio
₹32For every ₹100 of sales, ₹32 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹39 tied up three years earlier.
More money tied up than 65% of Healthcare companies in India.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Less steady than 68% of Healthcare companies in India.
Growth Efficiency Ratio
−₹7Sales grew 83% in 3 years, but profit fell: ₹7 less profit per ₹100 of extra sales.
Lower than 90% of Healthcare companies in India.
Asset Productivity Ratio
+83% / +84%In 3 years sales changed by +83% while total assets changed by +84%. Both moved at about the same pace.
Balance-sheet strength
Debt Due Cover Ratio
1.1×Debt due within a year is covered 1.1 times by its yearly operating cash.
Lower than 51% of Healthcare companies in India.
Cash Cushion Ratio
−7%Debt, after subtracting cash, equals 7% of its market value (net debt).
Lower than 71% of Healthcare companies in India.
Tangible Assets Ratio
97%Of every ₹100 the company owns, ₹97 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 51% of Healthcare companies in India.
Tangible Net Worth Ratio
95%Of every ₹100 of net worth, ₹95 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 51% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Orchid Pharma Limited owes ₹0.31 for every ₹1 it owns. Net profit fell 93% in the year to Mar 2026, and shrank 40% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
543.8Investors pay ₹543.8 for every ₹1 of Orchid Pharma Limited's yearly profit, higher than almost all Healthcare companies in India.
P/B ratio
2.84The share price is 2.84 times Orchid Pharma Limited's book value per share, lower than 73% of Healthcare companies in India.
Market cap
₹4,441 CrThe total market value of all of Orchid Pharma Limited's shares at today's price (share price × number of shares), smaller than 52% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹1,564 CrWhat Orchid Pharma Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹308.43Net worth divided by the number of shares. The share price of ₹875.55 is 2.8 times this, which is the P/B above.
Return on equity (ROE)
0.6%Orchid Pharma Limited earned 0.6% on its shareholders' money over the last year, lower than 91% of Healthcare companies in India.
Owes vs Owns
0.31×Orchid Pharma Limited owes ₹0.31 for every ₹1 it owns (low), lower than 66% of Healthcare companies in India.
Dividend yield
NoneOrchid Pharma Limited does not currently pay a dividend.
Revenue growth
-12%Revenue fell 12% in the year to Mar 2026, and grew 22% a year on average over 3 years.
Profit growth
-93%Net profit fell 93% in the year to Mar 2026, and shrank 40% a year on average over 3 years.
Profit margin
0.8%Orchid Pharma Limited keeps ₹1 of every ₹100 of revenue as net profit.
Cash quality
12.6×Cash from Orchid Pharma Limited's business was 12.6× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
4.5×Orchid Pharma Limited's operating profit covered its interest costs 4.5 times in the year to Mar 2026.
Cash vs debt
Net debtOrchid Pharma Limited had ₹299 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Orchid Pharma Limited's P/E ratio?
Investors pay ₹543.8 for every ₹1 of Orchid Pharma Limited's yearly profit, higher than almost all Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Orchid Pharma Limited: ₹4,441 Cr ÷ ₹1,564 Cr (31 Mar 2026) = 2.8.
What is Orchid Pharma Limited's return on equity?
Orchid Pharma Limited earned 0.6% on its shareholders' money over the last year, lower than 91% of Healthcare companies in India.
How much does Orchid Pharma Limited owe compared with what it owns?
Orchid Pharma Limited owes ₹0.31 for every ₹1 it owns (low), lower than 66% of Healthcare companies in India.
Does Orchid Pharma Limited pay a dividend?
No. Orchid Pharma Limited does not currently pay a dividend.
Is Orchid Pharma Limited's revenue growing?
Revenue fell 12% in the year to Mar 2026, and grew 22% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.